Clinical Role - Specialty Pharmacy

Pharmacy Times® is a leader in providing expert insights and clinical updates to specialty pharmacists and reaches more than 200,000 pharmacy professionals in total.

Pvsripo is a novel immunotherapy that activates patients’ innate and adaptive immune system to enable anti-tumor response and establish immunologic memory to prevent the recurrence of cancer.
A significantly greater proportion of patients with Crohn disease achieved both primary endpoints with overall safety results generally consistent with the known safety profile of risankizumab.
Darolutamide led to a 31% reduction in the risk of death, extending survival for patients with non-metastatic prostate cancer.
Pralatrexate, a lymphoma drug, outperformed remdesivir in treating COVID-19 in a lab experiment. 
According to the study authors, this could lead to finding the exact molecular trigger and gives hope for developing a targeted PsA treatment in the future.
Per Morten Sandset, MD, of the University of Oslo and Oslo University Hospital, discusses the treatment considerations necessary to properly manage a patient with congenital plasminogen deficiency after she became pregnant.
FDA approves request submitted by Moleculin Biotech, Inc. for rare disease designations to be granted their drug candidate that appears to directly elicit tumor cell death and prompt the immune system to eliminate tumors.
Pharmacists must juggle the delicate balance of integrating clinical services into traditional dispensing environments, while being forced into performance metrics set forth by corporate entities.
Pharmacy Times®, the leading multimedia resource for pharmacy professionals, adds the Association of Community Cancer Centers to its Strategic Alliance Partnership program.
Socioeconomic and racial health disparities contribute to worse cancer and COVID-19 outcomes. 
According to the study authors, previous small studies suggested that women taking statins may have less heart muscle damage from these types of chemotherapy, yet the exact mechanisms of how statins protect against the cardiac cell damage remains unknown.
The FDA has granted a breakthrough therapy designation to tiragolumab for use in combination with atezolizumab (Tecentriq) in the frontline treatment of patients with metastatic non­–small cell lung cancer.